Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Context Therapeutics Inc. (CNTX : NSDQ)

• Company Description    Context Therapeutics Inc. is a women's oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. Context Therapeutics Inc. is headquartered in Philadelphia, PA. Number of Employees: 15

• Price / Volume Information    Yesterday's Closing Price: $2.60 Daily Weekly Monthly 20 Day Moving Average: 740,314 shares Shares Outstanding: 91.88 (millions) Market Capitalization: $238.89 (millions) Beta: 1.57 52 Week High: $3.62 52 Week Low: $0.49 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 12.07% 6.59% 12 Week 14.04% 5.42% Year To Date 76.87% 50.10%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2001 MARKET STREET SUITE 3915 UNIT #15 - PHILADELPHIA,PA 19103 USA ph: 267-225-7416 fax: - ir@contexttherapeutics.com http://www.contexttherapeutics.com

• General Corporate Information    Officers Martin Lehr - Chief Executive Officer and Director Andy Pasternak - Chairman Jennifer Minai-Azary - Chief Financial Officer Karen Smith - Director Jennifer Evans Stacey - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 21077P108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/05/26 Share - Related Items Shares Outstanding: 91.88 Most Recent Split Date: (:1) Beta: 1.57 Market Capitalization: $238.89 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.08 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.35 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.58 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -80.00% vs. Previous Quarter: 35.71% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -59.95 12/31/25 - -47.04 09/30/25 - -30.93 ROA 03/31/26 - -54.78 12/31/25 - -44.08 09/30/25 - -29.59 Current Ratio 03/31/26 - 8.96 12/31/25 - 8.52 09/30/25 - 13.10 Quick Ratio 03/31/26 - 8.96 12/31/25 - 8.52 09/30/25 - 13.10 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 0.57 12/31/25 - 0.66 09/30/25 - 0.80 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©